Introduction
============

In 1999, Wolfe et al described nonsteroidal anti-inflammatory drug toxicity as a leading cause of mortality in the US, ahead of multiple myeloma, asthma, cervical cancer, and Hodgkin's disease, and similar to the acquired immunodeficiency syndrome.[@b1-ceor-8-413] A marked increase in reported deaths and serious injuries associated with drug therapy in the US highlighted the importance of this problem as a public health issue, providing strong evidence that postmarketing drug surveillance plays an increasingly important and essential role in the fields of clinical risk management and drug regulation, mainly in terms of assessing benefit/risk ratios, health economics, and public health.[@b2-ceor-8-413]

The growing evidence of the increased frequency and severity of adverse drug events (ADEs), besides the negative impact on patient's health status, indicates that costs due to ADEs may be steadily rising. The epidemiology of drug iatrogenesis across Europe has been identified as an area needing more study, particularly in the ambulatory health care environment, due to the scarcity of available data.[@b3-ceor-8-413] Furthermore, in some European countries, underreporting of ADEs has been identified as a pharmacovigilance shortcoming, anticipating that the economic burden of adverse effects of drugs may be underestimated.[@b3-ceor-8-413]

The costs of ADEs are a key component of the cost structure in health economic analysis and pharmacoeconomic studies. However, both data sources for ADE costs identification and methods of costs measurement vary among the different available studies.[@b4-ceor-8-413] Moreover, previous reviews pointed out a large methodological heterogeneity in measuring drug-induced morbidity.

Experimental and observational studies data can be used to estimate costs of ADEs. However, experimental studies are mainly designed to evaluate the efficacy of an intervention and the conclusions of ADEs and their related costs are difficult to draw due to their methodological limitations, such as length of exposure and the homogeneity of included patients. Observational studies, despite being more susceptible to bias, are more competent in assessing ADEs in clinical practice and allocating their costs than experimental studies.[@b5-ceor-8-413],[@b6-ceor-8-413]

In this light, a systematic review of observational studies was carried out aiming at identifying and characterizing the best available evidence on ADE-associated costs.

Methods
=======

This systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b7-ceor-8-413]

Literature search
-----------------

A systematic search was conducted from 1995 to 2015 in MEDLINE, Cochrane Library, and Embase to identify studies describing the costs of ADEs. Search terms related with costs of ADEs were identified consulting the Medical Subject Headings[@b8-ceor-8-413] and Emtree terms.[@b9-ceor-8-413] Only literature published in English language in the last 20 years was considered for inclusion in this analysis. The search strategy is listed in [Tables S1](#SD1-ceor-8-413){ref-type="supplementary-material"} and [S2](#SD2-ceor-8-413){ref-type="supplementary-material"}.

### Study selection and quality assessment

Two researchers independently screened by hand the titles and abstracts and selected full articles for inclusion. In case of disagreement, the opinion of a third investigator was sought.

Longitudinal and cross-sectional observational studies were eligible for inclusion if they had been conducted in the US or European countries, and reported on average costs of treating ADEs or reported enough data to perform such estimations.

For the purposes of this study, an ADE was defined according to the World Health Organization definition as "any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product".[@b10-ceor-8-413]

The quality of the retrieved studies was assessed using the checklist proposed by the Cochrane Collaboration for assessment of nonrandomized studies.[@b11-ceor-8-413]

Data extraction
---------------

Data on study design, study duration, data source, country, and setting of cost analysis were extracted in order to characterize the study design of the included studies. Additionally, data on study size, eligible patients, type of ADE(s) evaluated, drug(s) considered, type of cost analysis, cost component(s) assessed, and the estimated cost(s) were retrieved.

Studies were classified in two categories according to the type of costs analyzed: "ambulatory" if the costs estimated were of ADE(s) leading to hospitalization occurring in nonhospitalized patients, and in "hospital" if the costs estimated were of ADE(s) occurring during hospitalization.

Data analysis and presentation
------------------------------

Data were analyzed using descriptive statistics. The unit of measure of costs considered was the average incremental cost per patient with an ADE compared to a patient without an ADE. Some assumptions and conversions had to be made when studies reported other outcomes. As an example, if a study reported the incremental cost of treating a patient with an ADE over a month, that cost was converted to the total cost of treating a patient with an ADE irrespective of the time frame by considering the total number of patients analyzed and the average time of follow-up. The incremental cost was calculated as (\[consumer price index in 2014/consumer price index in the year of analysis\]\* incremental cost in the year of the study). All costs were presented in euros (€). The website of The Organisation for Economic Co-operation and Development was screened to identify currency exchange rates and consumer price indices per country.[@b12-ceor-8-413] Currency exchange rates established by the end of the year 2014 were used to convert other currencies to euros (€). Consumer price indices were used to adjust for the effect of costs' inflation estimated in studies conducted years ago to predicted costs by the year 2014. Data analyses were performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA).

Results
=======

The search yielded a total of 625 potentially relevant references. After excluding for duplicates, 458 abstracts were reviewed and screened for eligibility. Based on inclusion criteria, 90 references were selected for full-text further evaluation. A final sample of 31 studies was eligible for inclusion. The selection of references is shown in [Figure 1](#f1-ceor-8-413){ref-type="fig"}.

Characteristics of the selected studies
---------------------------------------

The 31 studies selected for further analyses included 22 cohort studies (71.0%), seven case--control studies (22.6%), and two studies based on pharmacovigilance databases of spontaneously reported ADEs (6.4%). [Table 1](#t1-ceor-8-413){ref-type="table"} describes the main characteristics of the studies. Seventeen cohort studies (77.3%) and six case--control studies (85.7%) were assessed as having a low risk of bias ([Table S3](#SD3-ceor-8-413){ref-type="supplementary-material"}).

The mean duration of the included studies was 19 months (53 days to 18 years). The studies were mainly conducted in the US (n=19; 61.3%).

Thirteen studies (41.9%) estimated the costs of ADEs occurring in the outpatient setting, ten studies (32.3%) estimated the costs both in "ambulatory" and "hospital" settings, and eight studies (25.8%) assessed the costs occurring during hospitalization.

Twenty studies (64.5%) did not evaluate any therapeutic group in particular. Among the studies which analyzed a specific therapeutic group, the costs of ADEs caused by medicines used for cancer treatment were the more commonly evaluated (n=6; 19.4%).

Most part of the studies assessed all ADEs resulting from the utilization of a drug. They not assessed a specific ADE (eg, skin toxicity related with erlotinib). Regarding studies assessing an ADE of a particular type, cutaneous events were the most evaluated (n=4; 12.9%).

Two studies (6.5%) evaluated the costs of ADEs in pediatric population and three studies (9.7%) studied specifically the geriatric population.[@b13-ceor-8-413]--[@b17-ceor-8-413]

Cost analysis
-------------

[Table 2](#t2-ceor-8-413){ref-type="table"} describes the costs analysis and the main results of the included studies.

A total of 29 (93.5%) studies evaluated "direct health care costs", and two studies (6.5%) issued both "direct and indirect health care costs". Costs related to facility expenses and treatment were the type of direct health care costs most assessed (n=18; 58%; n=17; 55%, respectively).

The costs of ADEs related to any drug occurring in nonhospitalized patients has been estimated from €702.21 to €40,273.08.[@b13-ceor-8-413],[@b14-ceor-8-413],[@b18-ceor-8-413]--[@b29-ceor-8-413] A study investigated the costs of ADEs related to rhythm-control, rate-control, and combined rhythm-/rate-control medication; the costs per patient with an ADE were estimated to be €2,737.46.[@b21-ceor-8-413] Leendertse et al assessed the costs of ADEs in geriatric population whereas Du et al estimated the costs of ADEs in pediatric population.[@b13-ceor-8-413],[@b14-ceor-8-413] The incremental total cost per patient with an ADE was estimated as €6,527.37 and €40,273.08, respectively.[@b13-ceor-8-413],[@b14-ceor-8-413]

The costs of ADEs that occurred during hospitalization varied from €943.40 to €5,972.74.[@b30-ceor-8-413]--[@b35-ceor-8-413] Hug et al compared the costs of any ADE, serious ADE, and life-threatening ADE; an increase in costs related to the seriousness of the ADEs was found (€3,030.79; €3,234.61; €7,192.36, respectively).[@b31-ceor-8-413] Another study estimated the costs of skin ADEs related to erlotinib as €1,105.54.[@b35-ceor-8-413]

Several studies assessed the costs of ADEs both in hospitalized and nonhospitalized patients ([Table 2](#t2-ceor-8-413){ref-type="table"}). The costs of skin ADEs related to antineoplastic agents were estimated from €1,592.89 to €15,037.97.[@b36-ceor-8-413],[@b37-ceor-8-413] A study evaluated the costs of nonserious and serious skin ADEs according to spontaneous reports; the incremental total cost per patient was estimated as €373.33 and €3,383.56, respectively.[@b38-ceor-8-413] Suh et al estimated the costs of levodopa-induced dyskinesia as €4,617.65.[@b39-ceor-8-413] Parekh et al assessed the costs of hypoglycemia in patients aged \>65 years as €25.41 per episode.[@b15-ceor-8-413] Another study investigated the costs of ADEs in pediatric population as €3,242.59.[@b17-ceor-8-413]

Few studies (n=2; 6.5%) assessed indirect health care costs of ADEs ([Table 3](#t3-ceor-8-413){ref-type="table"}). Leendertse et al estimated the indirect health care costs of any ADE leading to hospitalization as €1,982.41 for patients younger than 65 years and as €0.00 for patients aged 65 years or older, according to productivity costs including time off work and reduced productivity on the job.[@b13-ceor-8-413] Another study evaluated the indirect health care costs of any ADE both in hospitalized and nonhospitalized patients as €2,985.26.[@b36-ceor-8-413]

Discussion
==========

A wide range of values representing both incremental and total costs was found in this study, which may be explained by the methodological differences between included studies.

Of a total of 31 studies (19 from North-America and 12 from Europe), observational longitudinal designs (cohort \[n=22; 71%\] and case--control \[n=7; 23%\]) constituted the most frequent methodology observed (94%).

As pointed out by the results of this study, the identification of ADE costs has been focused on hospital setting in two ways: as cause of hospitalization or hospitalization prolongation. Therefore, studies were grouped according to the settings from where data were collected: nonhospitalized patients with ADEs leading to hospitalization, hospitalized patients with ADEs during the hospitalization, and a third group of ADEs simultaneously from outpatients and inpatients. In this last group, a specific setting could not be well established. Several reviews also illustrated these results.[@b4-ceor-8-413],[@b40-ceor-8-413],[@b41-ceor-8-413] The hospital setting was the privileged set for identification of ADEs and their costs. These data are easier to assess in administrative databases from hospitals while a complete description of each case was hard to obtain in ambulatory setting.[@b41-ceor-8-413]

Within the different above-established groups, several methodological heterogeneities were found. Some studies focused on the associations between any drug and any ADE, others on the association of one specific ADE, and several drugs or on the association between any ADE and one specific drug. The study of the association between one specific drug and one specific ADE was also found. Moreover, some studies only included serious ADEs, while others included serious and nonserious ADEs. In addition, some studies assessed ADEs treated in different hospital units, such as emergency departments and intensive care units, resulting in disparate values of ADE costs. For instance, in the study of Du et al, the incremental total cost per patient with ADE was estimated as €40,273.08, not only due to the specific population analyzed (pediatric) but also due to the setting analyzed (intensive care unit).[@b14-ceor-8-413] Another source of heterogeneity was the diversity of the drugs evaluated in the studies, which may have contributed to the high costs variation. Most of the studies included in this systematic review did not focus in any particular therapeutic group of drugs. Among the studies evaluating specific therapeutic groups (n=11), six were designed to estimate the costs associated with antineoplastic drugs. Of note, oncology was one of the therapeutic areas receiving more positive opinions for new active substances in recent years, both in Europe and the US.[@b42-ceor-8-413],[@b43-ceor-8-413] The study of the costs associated with treatments used in cancer is of upmost importance since these drugs are usually associated with a high burden of iatrogenics.[@b44-ceor-8-413]

Another source of heterogeneity was the metrics for cost evaluation in the different studies. Ninety percent of the studies solely identified direct costs, and different indexes were used for cost identification among studies. Information on indirect costs was difficult to access as it is associated with individual loss of productivity, and most studies evaluated different ADEs in a heterogeneous group of patients.[@b44-ceor-8-413]

The main strategy to identify ADEs and their related costs was the use of codes, such as International Classification of Diseases and Diagnosis-Related Group, and length of stay and their associated cost as an index measure.[@b4-ceor-8-413],[@b40-ceor-8-413],[@b41-ceor-8-413] Analysis of spontaneous reports, review of medical charts, and computer searches are some examples of the different methods used to detect ADEs.[@b45-ceor-8-413] Each of these methodologies had different sensitivities to identify ADEs, leading to a possible underestimation of the real number of ADEs, therefore, reflecting the heterogeneity of the observed results.[@b46-ceor-8-413]

The calculation of costs was also subject of heterogeneity. Whereas some studies estimated the costs per episode of ADE per patient, such as in Parekh et al which assessed the costs of one episode of hypoglycemia,[@b15-ceor-8-413] other studies estimated the costs of total ADEs per patient resulting from the total period of treatment, such as in oncology treatments.[@b16-ceor-8-413]

Data on the causality assessment between drug exposure and ADE were not available in any study. From a clinical and drug safety evaluation point of view, this is a relevant issue that should be included in future studies. However, when reflecting about ADE costs, investigators should carefully interpret studies as different causality methods can be applied,[@b47-ceor-8-413] as well as distinct definitions of ADE.[@b45-ceor-8-413] Such dissimilarities could lead to more heterogeneity. In addition, only for ADEs assessed as possible, probable and certain, the sensitivity analysis should be presented.[@b45-ceor-8-413]

The present findings are in line with the results from other studies. In fact, data on ADE costs not related with hospitalization are scarce, sometimes conflicting and mainly limited to direct costs. A more profound lack of knowledge on the subject is particularly seen in the ambulatory (outpatient) setting.[@b4-ceor-8-413],[@b40-ceor-8-413],[@b41-ceor-8-413]

This study has some limitations. The search was developed according to Medical Subject Headings and Emtree terms and only includes articles published in English, conducted in the US and Europe, and during the last 20 years. Methodological differences in the studies' designs can make the ADE cost impact assessment difficult. Such difficulties were encountered in this systematic review.

Despite the methodological discrepancies found between the studies included in this work, the burden of ADE costs is high, anticipating that the study of this issue deserves particular attention and further research efforts.

Supplementary materials
=======================

###### 

Search strategy -- Medline and Cochrane Library (MeSH)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Search   Search strategy
  -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        ("Costs and Cost Analysis"\[Mesh\] OR "Cost of Illness"\[Mesh\] OR "Drug Costs"\[Mesh\] OR "Hospital Costs"\[Mesh\] OR "Health Care Costs"\[Mesh\] OR "Cost-Benefit Analysis"\[Mesh\])

  2        "Drug-Related Side Effects and Adverse Reactions"\[Mesh\]

  3        \#1 AND \#2

  4        \#3\
           Filters: English; 20 years
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** MeSH, medical subject headings.

###### 

Search strategy--Embase (Emtree)

  -------------------------------------------------------------------------------------------------------------------------------
  Search   Search strategy
  -------- ----------------------------------------------------------------------------------------------------------------------
  1        "cost of illness"/exp OR "cost"/exp OR "health care costs"/exp OR "cost benefit analysis"/exp OR "hospital cost"/exp

  2        "drug induced disease"/exp/mj

  3        \#1 AND \#2

  4        \#3\
           Filters: English; 20 years
  -------------------------------------------------------------------------------------------------------------------------------

###### 

Methodological quality assessment results according to ACROBAT-NRS (2014) from Cochrane collaboration for cohort and case--control studies

  References/topics                                Bias due to confounding   Bias in selection of participants into the study   Bias in measurement of interventions   Bias due to departures from intended interventions   Bias due to missing data   Bias in measurement of outcomes   Bias in selection of the reported result   Overall bias
  ------------------------------------------------ ------------------------- -------------------------------------------------- -------------------------------------- ---------------------------------------------------- -------------------------- --------------------------------- ------------------------------------------ --------------
  Cohort studies                                                                                                                                                                                                                                                                                                                    
  Wan et al (2015)[@b51-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Gyllensten et al (2014)[@b52-ceor-8-413]         Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Parekh et al (2014)[@b53-ceor-8-413]             Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Du et al (2013)[@b54-ceor-8-413]                 Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Giuliani and Marzola, (2013)[@b55-ceor-8-413]    Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Ray et al (2013)[@b56-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Rottenkolber et al (2012)[@b57-ceor-8-413]       Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Suh et al (2012)[@b58-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Hug et al (2012)[@b59-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Borovicka et al (2011)[@b60-ceor-8-413]          Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Paessens et al (2011)[@b61-ceor-8-413]           Moderate                  Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Moderate
  Carrasco-Garrido et al (2010)[@b62-ceor-8-413]   Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Foley et al (2010)[@b63-ceor-8-413]              Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Kim et al (2009)[@b64-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Lang et al (2009)[@b65-ceor-8-413]               Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Pirmohamed et al (2004)[@b66-ceor-8-413]         Low                       Low                                                Moderate                               NA                                                   Low                        Low                               Low                                        Moderate
  Yee et al (2005)[@b67-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Moderate                                   Moderate
  Schneeweiss et al (2002)[@b68-ceor-8-413]        Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Bordet et al (2001)[@b69-ceor-8-413]             Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Lagnaoui et al (2000)[@b70-ceor-8-413]           Low                       Low                                                Moderate                               NA                                                   Low                        Low                               Low                                        Moderate
  Tafreshi et al (1999)[@b71-ceor-8-413]           Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Schneider et al (1995)[@b72-ceor-8-413]          Moderate                  Low                                                Moderate                               NA                                                   Low                        Low                               Moderate                                   Moderate
  Case--control studies                                                                                                                                                                                                                                                                                                             
  Tundia et al (2011)[@b73-ceor-8-413]             Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Leendertse et al (2011)[@b74-ceor-8-413]         Low                       Low                                                Low                                    NA                                                   Low                        Low                               Serious                                    Moderate
  Hafner et al (2002)[@b75-ceor-8-413]             Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Senst et al (2001)[@b76-ceor-8-413]              Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Suh et al (2000)[@b77-ceor-8-413]                Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Bates et al (1997)[@b78-ceor-8-413]              Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low
  Classen et al (1997)[@b79-ceor-8-413]            Low                       Low                                                Low                                    NA                                                   Low                        Low                               Low                                        Low

**Notes:** Low, low risk of bias (the study is comparable to a well-performed randomized trial with regard to this domain); moderate, moderate risk of bias (the study is sound for a nonrandomized study with regard to this domain but cannot be considered comparable to a well-performed randomized trial); serious risk of bias (the study has some important problems in this domain); critical risk of bias (the study is too problematic in this domain to provide any useful evidence on the effects of intervention). Data from <https://www.nlm.nih.gov/mesh/MBrowser.html>.[@b80-ceor-8-413]

**Abbreviations:** ACROBAT-NRS, assessment tool for nonrandomized studies of interventions; NA, not applicable.
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![Flow diagram of literature search.\
**Notes:** \*The references are not available on the electronic databases searched. The publications' authors did not reply to our request to access the publication's full-text.](ceor-8-413Fig1){#f1-ceor-8-413}

###### 

Main characteristics of the included studies

  Study                                            Design                                                     Country           Study period            Setting                    Characteristics of the patients                                                                                          Suspected drug(s)                                                Type of ADE                                             Type and structure of costs                                                                                                                                                                                                                                                                                                                                                                         Risk of bias
  ------------------------------------------------ ---------------------------------------------------------- ----------------- ----------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  Pirmohamed et al (2004)[@b18-ceor-8-413]         Prospective cohort study                                   England           6 months                Outpatient                 Patients aged \>16 years admitted to hospital                                                                            Any drug                                                         Any ADE                                                 Costs: total time spent in hospital, and invasive investigations performed                                                                                                                                                                                                                                                                                                                          Moderate
  Bordet et al (2001)[@b19-ceor-8-413]             Prospective cohort study                                   France            18 months               Outpatient                 Patients admitted to a cardiological hospital                                                                            Any drug                                                         Any ADE                                                 Direct costs: A) additional investigations, B) laboratory tests, C) noninvasive procedures, D) invasive monitoring or procedures, E) additional treatment, and F) increased length of stay                                                                                                                                                                                                          Low
  Carrasco-Garrido et al (2010)[@b20-ceor-8-413]   Retrospective cohort study                                 Spain             6 years                 Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Direct medical costs                                                                                                                                                                                                                                                                                                                                                                                Low
  Kim et al (2009)[@b21-ceor-8-413]                Retrospective cohort study                                 US                5 years                 Outpatient                 Patients treated for atrial fibrillation                                                                                 Rhythm-control, rate-control, and combined rhythm/rate-control   Any ADE                                                 Direct medical costs: inpatient (facility and professional) and outpatient (medical, laboratory, and pharmacy)                                                                                                                                                                                                                                                                                      Low
  Yee et al (2005)[@b22-ceor-8-413]                Retrospective cohort study                                 US                1 year                  Outpatient                 Patients aged \>18 years who visited the ED                                                                              Any drug                                                         Any ADE                                                 Costs: drugs administered, laboratory tests, and follow-up outpatient clinic visits                                                                                                                                                                                                                                                                                                                 Moderate
  Lagnaoui et al (2000)[@b23-ceor-8-413]           Retrospective cohort study                                 France            4 months                Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Costs: length of stay and hospitalization costs                                                                                                                                                                                                                                                                                                                                                     Moderate
  Leendertse et al (2011)[@b13-ceor-8-413]         Prospective case--control study                            The Netherlands   53 days                 Outpatient                 Patients aged \>18 years admitted to hospital                                                                            Any drug                                                         Preventable ADE-induced hospitalization                 Medical costs during hospital admission; production loss costs: time off work and reduced productivity on the job                                                                                                                                                                                                                                                                                   Moderate
  Hafner et al (2002)[@b24-ceor-8-413]             Retrospective case--control study                          US                3 months                Outpatient                 Patients who visited the ED                                                                                              Any drug                                                         Any ADE                                                 Costs: hospitalized days and hospitalized charges                                                                                                                                                                                                                                                                                                                                                   Low
  Bates et al (1997)[@b25-ceor-8-413]              Prospective case--control study                            US                6 months                Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Costs: intensive care unit, intermediate and routine care, pharmacy, laboratory, and surgery                                                                                                                                                                                                                                                                                                        Low
  Rottenkolber et al (2011)[@b26-ceor-8-413]       PV database[\*](#tfn1-ceor-8-413){ref-type="table-fn"}     Germany           2 years                 Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Spontaneously reported ADE leading to hospitalization   Direct costs: A) hospitalizations; B) medical consultations; C) laboratory tests; and D) drug treatments                                                                                                                                                                                                                                                                                            --
  Senst et al (2001)[@b27-ceor-8-413]              Prospective case--control study                            US                53 days                 Inpatient and outpatient   Patients having ADE during hospitalization and patients admitted to hospital due to ADE                                  Any drug                                                         Any ADE                                                 Costs of resource use                                                                                                                                                                                                                                                                                                                                                                               Low
  Tafreshi et al (1999)[@b28-ceor-8-413]           Prospective cohort study                                   US                2 months                Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Costs: total cost to the institution, not charges to the patient, or third-party payers, including overhead costs such as personnel and supplies                                                                                                                                                                                                                                                    Low
  Schneeweiss et al (2002)[@b29-ceor-8-413]        Prospective cohort study                                   Germany           2 years and 6 months    Outpatient                 Patients admitted to hospital                                                                                            Any drug                                                         Any ADE, except skin ADE                                Costs: reimbursement per hospital day                                                                                                                                                                                                                                                                                                                                                               Low
  Du et al (2013)[@b14-ceor-8-413]                 Prospective cohort study                                   US                7 months                Outpatient                 Children (median age 4 years) admitted to ICU                                                                            Any drug                                                         Any ADE                                                 Costs: facility-based cost data                                                                                                                                                                                                                                                                                                                                                                     Low
  Rottenkolber et al (2012)[@b30-ceor-8-413]       Retrospective cohort study with a case--control analysis   Germany           1 year                  Inpatient and outpatient   Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Direct medical costs: personnel costs (clinicians, nursing staff, and medical technicians) and nonpersonnel costs (pharmaceuticals, implants, grafts, and medical expenditure not otherwise specified); medical and nonmedical infrastructures (general ward, intensive care units, operating room, anesthesia, cardiac and endoscopic diagnoses and therapies, radiology, laboratory tests, etc)   Low
  Hug et al (2012)[@b31-ceor-8-413]                Retrospective cohort study                                 US                20 months               Inpatient                  Patients aged \>18 years being treated in hospital                                                                       Any drug                                                         Any ADE                                                 Diagnosis-related group weighted hospitalization cost and cost of length of stay                                                                                                                                                                                                                                                                                                                    Low
  Schneider et al (1995)[@b32-ceor-8-413]          Retrospective cohort study                                 US                2 years                 Inpatient                  Patients having an MRP during hospitalization                                                                            Any drug                                                         Any ADE                                                 Direct costs: A) extra laboratory tests, B) noninvasive procedures, C) additional treatments, D) invasive monitoring or procedures, E) increased length of stay, and F) intensive care                                                                                                                                                                                                              Moderate
  Suh et al (2000)[@b33-ceor-8-413]                Prospective case--control study                            US                5 months                Inpatient                  Patients having ADE during hospitalization                                                                               Any drug                                                         Any ADE                                                 Costs: length of stay and hospitalization costs                                                                                                                                                                                                                                                                                                                                                     Low
  Classen et al (1997)[@b34-ceor-8-413]            Retrospective case--control study                          US                4 years                 Inpatient                  Patients admitted to hospital                                                                                            Any drug                                                         Any ADE                                                 Cost of hospitalization                                                                                                                                                                                                                                                                                                                                                                             Low
  Giuliani and Marzola (2013)[@b35-ceor-8-413]     Retrospective cohort study                                 Italy             5 years                 Inpatient                  Patients with NSCLC                                                                                                      Erlotinib                                                        Skin toxicity                                           Direct medical costs: based on mean duration of skin rash and range of costs related to different drug prices                                                                                                                                                                                                                                                                                       Low
  Gyllensten et al (2014)[@b36-ceor-8-413]         Retrospective cohort study                                 Sweden            3 months                Inpatient and outpatient   Patients aged \>18 years with health care encounters                                                                     Any drug                                                         Any ADE                                                 Costs: hospitalized days and hospitalized charges                                                                                                                                                                                                                                                                                                                                                   Low
  Lang et al (2009)[@b48-ceor-8-413]               Retrospective cohort study                                 US                6 years                 Inpatient and outpatient   Patients aged \>35 years with advanced squamous cell carcinoma of the head and neck                                      Radiotherapy, chemoradiotherapy                                  Any ADE                                                 Costs: A) hospital inpatient, B) hospital outpatient, C) physician, and D) outpatient pharmacy                                                                                                                                                                                                                                                                                                      Low
  Paessens et al (2011)[@b49-ceor-8-413]           Prospective cohort study                                   Germany           2 years and 6 months    Inpatient and outpatient   Patients undergoing multidrug chemotherapy with NSCLC and lymphoproliferative disorder                                   Multidrug chemotherapy                                           Any ADE                                                 Costs: cost of hospitalization, cost of drugs, medical treatment, and diagnostic procedures                                                                                                                                                                                                                                                                                                         Moderate
  Ray et al (2013)[@b50-ceor-8-413]                Retrospective cohort study                                 US                10 years and 7 months   Inpatient and outpatient   Patients with CRC, NSCLC, or HNC                                                                                         EGFRI                                                            Dermatologic ADE                                        Costs: pharmacy (EGFRI drug costs, other pharmacy costs), medical services (admissions, ED visits, outpatient visits, other medical services, ie, laboratory, radiology), and total costs (pharmacy and medical costs)                                                                                                                                                                              Low
  Borovicka et al (2011)[@b37-ceor-8-413]          Retrospective cohort study                                 US                2 years and 8 months    Inpatient and outpatient   Patients diagnosed with cancer receiving one molecularly targeted agent                                                  Molecularly targeted cancer agents                               Dermatologic ADE                                        Costs for medications, clinic visits, laboratory and diagnostic testing, and therapeutic procedures                                                                                                                                                                                                                                                                                                 Low
  Noize et al (2010)[@b38-ceor-8-413]              PV database[\*](#tfn1-ceor-8-413){ref-type="table-fn"}     France            18 years                Inpatient and outpatient   Any                                                                                                                      Ketoprofen for topical use                                       Spontaneously reported cutaneous ADE                    Direct costs: A) hospitalizations, B) medical consultations, C) laboratory tests, and D) drug treatments                                                                                                                                                                                                                                                                                            --
  Suh et al (2012)[@b39-ceor-8-413]                Retrospective cohort study                                 US                5 years                 Inpatient and outpatient   Patients aged \>18 years with PD                                                                                         Levodopa                                                         Dyskinesia                                              Medical costs: hospitalizations, outpatient services, and ED; Medication costs: dispensed by outpatient, community-based, or mail-service pharmacies                                                                                                                                                                                                                                                Low
  Foley et al (2010)[@b44-ceor-8-413]              Retrospective cohort study                                 US                3 years                 Inpatient and outpatient   Patients with CRC                                                                                                        Cetuximab                                                        Infusion ADE                                            Costs: A) inpatient care, B) inpatient length of stay, C) ED, D) outpatient care, and E) prescription                                                                                                                                                                                                                                                                                               Low
  Parekh et al (2014)[@b15-ceor-8-413]             Retrospective cohort study                                 US                4 years                 Inpatient and outpatient   Patients aged \>65 years with diabetes and a concomitant infection                                                       Antimicrobial drugs                                              Hypoglycemia                                            Costs: emergency department services, hospitalizations, and professional services                                                                                                                                                                                                                                                                                                                   Low
  Wan et al (2015)[@b16-ceor-8-413]                Retrospective cohort study                                 US                1 year                  Inpatient and outpatient   Patients aged \>18 years                                                                                                 Opioids                                                          Constipation                                            Costs: costs for inpatient, pharmacy, outpatient, emergency department, long-term care facility, and other costs                                                                                                                                                                                                                                                                                    Low
  Tundia et al (2011)[@b17-ceor-8-413]             Retrospective case--control study                          US                1 year                  Inpatient and outpatient   Children and adolescents aged ≤20 years having ADE during hospitalization and patients admitted to hospital due to ADE   Any drug                                                         Pediatric ADE                                           Hospital costs, length of stay                                                                                                                                                                                                                                                                                                                                                                      Low

**Notes:**

Methodological quality was not assessed for pharmacovigilance databases studies.

**Abbreviations:** ADE, adverse drug event; CRC, colorectal cancer; ED, emergency department; EGFRI, epidermal growth factor receptor inhibitor; HNC, head and neck cancer; ICU, Intensive care unit; MRP, medication-related problems; NSCLC, non-small-cell lung cancer; PD, Parkinson disease; PV, pharmacovigilance.

###### 

Incremental total direct health care cost per patient with ADE (€)

  Type of ADE                                                                                                                         Reference                                                                         Drug                       Incremental total cost per patient with ADE (€)
  ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------- -------------------------------------------------
  **Nonhospitalized patients with ADEs leading to hospitalization**                                                                                                                                                                                
                                                                                                                                                                                                                                                   
  Any ADE                                                                                                                             Pirmohamed et al (2004)[@b18-ceor-8-413]                                          Any drug                   3,682.82
  Bordet et al (2001)[@b19-ceor-8-413]                                                                                                Any drug                                                                          5,187.50                   
  Carrasco-Garrido et al (2010)[@b20-ceor-8-413]                                                                                      Any drug                                                                          4,910.12                   
  Kim et al (2009)[@b21-ceor-8-413]                                                                                                   Rhythm-control, rate-control, and combined rhythm-/rate-control drug              2,737.46                   
  Yee et al (2005)[@b22-ceor-8-413]                                                                                                   Any drug                                                                          3,593.60                   
  Lagnaoui et al (2000)[@b23-ceor-8-413]                                                                                              Any drug                                                                          3,500.80                   
  Leendertse et al (2011)[\*](#tfn3-ceor-8-413){ref-type="table-fn"}, [‡](#tfn6-ceor-8-413){ref-type="table-fn"}, [@b13-ceor-8-413]   Any drug                                                                          5,891.65                   
  Hafner et al (2002)[@b24-ceor-8-413]                                                                                                Any drug                                                                          702.21                     
  Bates et al (1997)[@b25-ceor-8-413]                                                                                                 Any drug                                                                          3,209.82                   
  Bates et al (1997)[‡](#tfn6-ceor-8-413){ref-type="table-fn"},[@b25-ceor-8-413]                                                      Any drug                                                                          5,794.99                   
  Rottenkolber et al (2011)[@b26-ceor-8-413]                                                                                          Any drug                                                                          2,427.45                   
  Rottenkolber et al (2012)[@b30-ceor-8-413]                                                                                          Any drug                                                                          2,140.49                   
  Senst et al (2001)[@b27-ceor-8-413]                                                                                                 Any drug                                                                          7,318.14                   
  Tafreshi et al (1999)[@b28-ceor-8-413]                                                                                              Any drug                                                                          1,303.40                   
  Any ADE, except skin ADE                                                                                                            Schneeweiss et al (2002)[@b29-ceor-8-413]                                         Any drug                   820.16
  Any ADE in pediatric population                                                                                                     Du et al (2013)[@b14-ceor-8-413]                                                  Any drug                   40,273.08
  Any ADE in geriatric population                                                                                                     Leendertse et al (2011)[@b13-ceor-8-413]                                          Any drug                   6,527.37
                                                                                                                                                                                                                                                   
  **Hospitalized patients with ADEs during the hospitalization**                                                                                                                                                                                   
                                                                                                                                                                                                                                                   
  Any ADE                                                                                                                             Rottenkolber et al (2012)[@b30-ceor-8-413]                                        Any drug                   1,049.69
  Senst et al (2001)[@b27-ceor-8-413]                                                                                                 Any drug                                                                          2,366.77                   
  Hug et al (2012)[¥](#tfn7-ceor-8-413){ref-type="table-fn"},[@b31-ceor-8-413]                                                        Any drug                                                                          3,030.79                   
  Hug et al (2012)[µ](#tfn8-ceor-8-413){ref-type="table-fn"},[@b31-ceor-8-413]                                                        Any drug                                                                          3,234.61                   
  Hug et al (2012)[§](#tfn9-ceor-8-413){ref-type="table-fn"},[@b31-ceor-8-413]                                                        Any drug                                                                          7,192.36                   
  Schneider et al (1995)[@b32-ceor-8-413]                                                                                             Any drug                                                                          943.40                     
  Suh et al (2000)[@b33-ceor-8-413]                                                                                                   Any drug                                                                          5,972.74                   
  Classen et al (1997)[@b34-ceor-8-413]                                                                                               Any drug                                                                          2,797.92                   
  Skin ADE                                                                                                                            Giuliani and Marzola (2013)[@b35-ceor-8-413]                                      Erlotinib                  1,105.54
                                                                                                                                                                                                                                                   
  **Other (both hospitalized and nonhospitalized patients; spontaneous reports)**                                                                                                                                                                  
                                                                                                                                                                                                                                                   
  Any ADE                                                                                                                             Gyllensten et al (2014)[@b36-ceor-8-413]                                          Any drug                   349.98
  Lang et al (2009)[@b48-ceor-8-413]                                                                                                  Radiotherapy, chemoradiotherapy                                                   8,509.24                   
  Paessens et al (2011)[@b49-ceor-8-413]                                                                                              Multidrug chemotherapy                                                            4,213.97                   
  Skin ADE                                                                                                                            Ray et al (2013)[@b50-ceor-8-413]                                                 Panitumumab or cetuximab   13,150.34
  Ray et al (2013)[@b50-ceor-8-413]                                                                                                   Erlotinib or gefitinib                                                            14,860.76                  
  Ray et al (2013)[@b50-ceor-8-413]                                                                                                   Cetuximab                                                                         15,037.97                  
  Borovicka et al (2011)[@b37-ceor-8-413]                                                                                             Molecularly targeted cancer agents                                                1,592.89                   
  Noize et al (2010)[¥](#tfn7-ceor-8-413){ref-type="table-fn"},[@b38-ceor-8-413]                                                      Ketoprofen for topical use                                                        373.33                     
  Noize et al (2010)[µ](#tfn8-ceor-8-413){ref-type="table-fn"},[@b38-ceor-8-413]                                                      Ketoprofen for topical use                                                        3,383.56                   
  Dyskinesia                                                                                                                          Suh et al (2012)[@b39-ceor-8-413]                                                 Levodopa                   4,617.65
  Infusion ADE[β](#tfn11-ceor-8-413){ref-type="table-fn"}                                                                             Foley et al (2010)[α](#tfn10-ceor-8-413){ref-type="table-fn"},[@b44-ceor-8-413]   Cetuximab                  5,603.70
  Hypoglycemia                                                                                                                        Parekh et al (2014)[□](#tfn5-ceor-8-413){ref-type="table-fn"},[@b15-ceor-8-413]   Antimicrobial drugs        25.41
  Constipation                                                                                                                        Wan et al (2015)[\*](#tfn3-ceor-8-413){ref-type="table-fn"},[@b16-ceor-8-413]     Opioids                    8,711.33
  Constipation                                                                                                                        Wan et al (2015)[£](#tfn4-ceor-8-413){ref-type="table-fn"},[@b16-ceor-8-413]      Opioids                    4,606.79
  Constipation                                                                                                                        Wan et al (2015)[§](#tfn9-ceor-8-413){ref-type="table-fn"},[@b16-ceor-8-413]      Opioids                    1,240.17
  Any ADE in pediatric population                                                                                                     Tundia et al (2011)[@b17-ceor-8-413]                                              Any drug                   3,242.59

**Notes:**

Population aged \<65 years;

population aged 18\< n \<65 years;

population aged \>65 years;

preventable;

any ADE;

only serious ADE;

only life-threatening ADE;

mean of both hospitalized and nonhospitalized patients;

allergic and hypersensitivity ADE; ¤patients with long-term treatment with opioids.

**Abbreviation:** ADE, adverse drug event.

###### 

Incremental total indirect health care cost per patient with ADE (€)

  Type of ADE                                                                       Reference                                                                               Drug       Incremental total cost per patient with ADE (€)
  --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------- -------------------------------------------------
  **Nonhospitalized patients with ADEs leading to hospitalization**                                                                                                                    
                                                                                                                                                                                       
  Any ADE                                                                           Leendertse et al (2011)[\*](#tfn13-ceor-8-413){ref-type="table-fn"},[@b13-ceor-8-413]   Any drug   1,982.41
  Any ADE in geriatric population                                                   Leendertse et al (2011)[@b13-ceor-8-413]                                                Any drug   0.00
                                                                                                                                                                                       
  **Other (both hospitalized and nonhospitalized patients; spontaneous reports)**                                                                                                      
                                                                                                                                                                                       
  Any ADE                                                                           Gyllensten et al (2014)[@b36-ceor-8-413]                                                Any drug   2,985.26

**Note:**

Population \<65 years.

**Abbreviation:** ADE, adverse drug event.
